Rafael Holdings

Historical price data

Rafael Holdings is a clinical-stage biotech focused on developing novel oncology and rare disease therapeutics. Its core mission is to improve and extend the lives of patients with difficult-to-treat diseases by targeting cancer metabolism and lysosomal function. The company's strategy leverages its lead asset, devimistat, in late-stage trials for solid tumors and hematologic malignancies, while integrating new platforms through strategic mergers. With two Phase 3 trials ongoing and a recent expansion into rare diseases, Rafael is transitioning from a clinical-stage entity toward a potential commercial enterprise.

Two core platforms: 1) Cancer metabolism targeting via inhibition of mitochondrial TCA cycle enzymes (devimistat), and 2) Cyclodextrin-based cholesterol mobilization for lysosomal storage disorders (Trappsol® Cyclo™).

In cancer metabolism, faces competition from companies like Agios/Service and Forma/Novo Nordisk, and broader competition from all oncology modalities. In NPC1, competes with other investigational therapies including gene therapies. Differentiation hinges on demonstrating superior efficacy/safety of its unique mechanisms of action.